Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QULOX: Qutenza versus duloxetine for painful chemotherapy-induced peripheral neuropathy
NL-OMON53741Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Qutenza with duloxetine (2 arms). Primary endpoint: Pain severity at week 12. Started Oct 2022; status: recruiting.
02
Drugs
capsaicinduloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NL-OMON53741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53741.